United Therapeutics (UTHR) Tops Q2 EPS by 82c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $611.90 +1.76%
Financial Fact:
Total operating expenses: 169.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Financial Fact:
Total operating expenses: 169.6M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $3.98, $0.82 better than the analyst estimate of $3.16. Revenue for the quarter came in at $444.5 million versus the consensus estimate of $368.58 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- SelectQuote, Inc. (SLQT) Tops Q1 EPS by 13c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
